Evidence map›Paper›PMID 32156491›Full record

ArticleEuropean urology focus2021

Clinical-genomic Characterization Unveils More Aggressive Disease Features in Elderly Prostate Cancer Patients with Low-grade Disease.

Hanan Goldberg, Daniel Spratt, Thenappan Chandrasekar, Zachary Klaassen, Christopher J D Wallis, Maria Santiago-Jimenez, Nick Fishbane, Elai Davicioni, Rodrigo Noorani, Ardalan E Ahmad and 4 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in European urology focus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02609269 (Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02609269 enrolling by invitationnot on this map

Prospective Expression Analysis Using The Decipher Genomics Resource for Intelligent Discovery (GRID)® and Data Sharing Program

Typeobservational_patient_registrySponsorGenomeDx Biosciences CorpRan2015 to 2040Enrolled1,000,000ConditionsProstate Cancer, Bladder Cancer, Renal CancerArmsDecipher Cancer Classifier
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Hanan GoldbergDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada; Department of Urology, SUNY Upstate Medical University, Syracuse, NY, USA. Electronic address: gohanan@gmail.com.
Daniel SprattDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA.
Thenappan ChandrasekarDepartment of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Zachary KlaassenDivision of Urology, Department of Surgery, Medical College of Georgia, Augusta University, Augusta, GA, USA; Georgia Cancer Center, Augusta, GA, USA.
Christopher J D WallisDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Maria Santiago-JimenezDecipher Biosciences, Vancouver, BC, Canada.
Nick FishbaneDecipher Biosciences, Vancouver, BC, Canada.
Elai DavicioniDecipher Biosciences, Vancouver, BC, Canada.
Rodrigo NooraniDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Ardalan E AhmadDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Jaime Omar Herrera CáceresDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.
Shabbir AlibhaiDepartment of Medicine, University Health Network, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada.
Alejandro BerlinRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada; Techna Institute, University Health Network, Toronto, ON, Canada.
Neil Eric FleshnerDivision of Urology, Department of Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver 20% of men diagnosed with prostate cancer (PC) are ≥75 yr old. More objective disease-specific indices for predicting outcomes beyond chronological age are necessary.

objectiveTo analyze age-related differences in clinical-genomic prognostic features of aggressiveness in localized PC. DESIGN, SETTING, AND

participantsA retrospective multicenter cross-sectional study reported the use of the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) guidelines. Clinical-genomic data of patients who underwent a prostate biopsy or radical prostatectomy (RP) were obtained from the Decipher Genomic Resource Information Database (NCT02609269).

interventionOur analyses focused on the 22-gene Decipher genomic classifier (GC) and 50-gene (PAM50) models in the biopsy and RP cohorts stratified by age. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was the impact of age on GC scores and PAM50 molecular subtypes. Prognostic indices including Decipher GC scores, PAM50 molecular subtypes, National Comprehensive Cancer Network risk categories, and ISUP grade groups (IGGs) were stratified by age using multivariable logistic regression analyses. RESULTS AND LIMITATIONS: Within histological low-risk IGGs, there were a higher proportion of patients with high-risk Decipher biopsy scores with age (age <60 yr: 10.1% IGG 1 and 29.9% IGG 2 vs age ≥80 yr: 22% IGG 1 and 37.7% IGG 2). The prevalence of the adverse phenotype luminal B (PAM50-defined) increased with age (age <60 yr: 22.7% and 40.2% vs age ≥80 yr: 29.7% and 49.1%, in patients with IGG 1 and IGG 2, respectively). In IGGs 3-5, no age differences were observed. Multivariable models demonstrated that each age decile entailed a 19% (odds ratio [OR] 1.19, 95% confidence interval [CI] 1.10-1.29, p < 0.001) and a 10% (OR 1.1, 95% CI 1.05-1.16) increased probability for a high-risk Decipher biopsy and RP score, respectively. Aside from an obvious selection bias, data on race, family history, prostate volume, and long-term follow-up outcomes were unavailable.

conclusionsThese data demonstrated that elderly men with favorable pathology (IGG 1-2), might harbor more aggressive disease than younger patients based on validated GC scores. PATIENT SUMMARY: The presented clinical-genomic data demonstrate that elderly patients with low-risk prostate cancer might harbor more aggressive disease than their younger counterparts. This suggests that standard well-accepted paradigm of elderly prostate cancer patients not being aggressively treated, based solely on their chronological age, might need to be reconsidered.

Indexed as

Prostatic NeoplasmsAgedCross-Sectional StudiesHumansImmunoglobulin GMaleProstatectomyRetrospective StudiesImmunoglobulin GAgeDecipherGenomic classifierGleason group gradeProstate cancer

Identifiers

PMID32156491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.